Modern ethical aspects of clinical trials in patients with multiple sclerosis

Cover Page

Abstract

In this article, universal guidelines and requirements to clinical trials of new drugs in multiple sclerosis are presented. Principles of patients’ informed consent, various ethical aspects and possible problems occurring in the course of clinical trials in these patients are discussed in detail. Presented are main current documents regulating clinical trials of new drugs in the Russian Federation.

 

About the authors

E. V. Ivashkova

N.P. Behtereva Institute of Human Brain, Russian Academy of Sciences (St. Petersburg)

Author for correspondence.
Email: platonova@neurology.ru
Russian Federation

A. M. Petrov

N.P. Behtereva Institute of Human Brain, Russian Academy of Sciences (St. Petersburg)

Email: platonova@neurology.ru
Russian Federation

M. V. Votintseva

N.P. Behtereva Institute of Human Brain, Russian Academy of Sciences (St. Petersburg)

Email: platonova@neurology.ru
Russian Federation

G. G. Shkilnyuk

N.P. Behtereva Institute of Human Brain, Russian Academy of Sciences (St. Petersburg)

Email: platonova@neurology.ru
Russian Federation

I. D. Stolyarov

N.P. Behtereva Institute of Human Brain, Russian Academy of Sciences (St. Petersburg)

Email: platonova@neurology.ru
Russian Federation

References

  1. Бойко А.Н., Столяров И.Д., Петров А.М. и др. Перспективы новых методов патогенетической терапии рассеянного склероза. Неврол. вестник 2010; 1: 157–159.
  2. Малышева Е.А., Мохов О.И.Информированное согласие в клинических испытаниях лекарственных средств. Качественная клиническая практика 2002; 1: 1–5.
  3. Рассеянный склероз и другие демиелинизирующие заболевания (под ред. Е.И. Гусева, И.А. Завалишина, А.Н. Бойко). М.: Миклош, 2004.
  4. Рассеянный склероз: диагностика, лечение, специалисты (под ред. И.Д. Столярова, А.Н. Бойко). СПб: Элби-СПб, 2008.
  5. Приказ Министерства здравоохранения и социального развития Российской Федерации от 31 августа 2010 г. № 774н «О Совете по этике».
  6. Федеральный закон от 12.04.2010 № 61-ФЗ «Об обращении лекарственных средств».
  7. Хельсинкская декларация Всемирной медицинской ассоциации: рекомендации для врачей по проведению биомедицинских исследований на людях. М., 2008.
  8. Comi G., Abramsky O., Arbizu T. et al. Oral laquinimod in patients with relapsing-remitting MS: 9-month double-blind active extension of the multicentre, randomized, double-blind, parallel-group placebocontrolled study. Multiple Sclerosis 2008; 14: 27–31.
  9. Emanuel E.J., Wendler D., Grady C. What makes clinical research ethical? JAMA 2000; 283: 2701–2711.
  10. EMEA need for Revision of the Note for Guideline on clinical investigation of medicinal products for the treatment of multiple sclerosis, 2005.
  11. Kappos L., Radue E.W., O’Connor P. et al. Oral fingolimod in patients with relapsing MS: 3-year results from a phase II study extension. Multiple Sclerosis 2008; 14 (Suppl. 1): P72.
  12. Lublin F.D. Placebo-controlled clinical trials in multiple sclerosis: Ethical Considerations. Ann. Neurol. 2001; 49: 677–681.
  13. O’Connor P., Confavreux C., Comi G. et al. Oral teriflunomide in patients with relapsing MS: baseline clinical features of patients in the TEMSO phase III trial. Multiple sclerosis 2008; 14 (Suppl.1): S85.
  14. Polman C.H. Ethics of placebo controlled clinical trials in multiple sclerosis: a reassessment. Neurology 2009; 72: 1191–1192.
  15. Pryse-Phillips W. Ethical considerations for clinical trial design in MS. The International MS Journal 2002; 9: 9–15.

Statistics

Views

Abstract: 979

PDF (Russian): 540

Article Metrics

Metrics Loading ...

Dimensions

PlumX


Copyright (c) 2017 Ivashkova E.V., Petrov A.M., Votintseva M.V., Shkilnyuk G.G., Stolyarov I.D.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies